IRMD · Iradimed Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $83.81M | $73.24M | $65.56M | $53.30M | $41.81M | $31.72M |
| Cost of Revenue | $19.49M | $16.89M | $15.40M | $12.02M | $9.76M | $8.14M |
| Gross Profit | $64.32M | $56.35M | $50.16M | $41.28M | $32.05M | $23.57M |
| R&D | $2.98M | $2.83M | $2.86M | $2.28M | $1.91M | $1.90M |
| SG&A | $17.78M | $15.94M | $15.12M | $10.70M | $9.77M | $12.27M |
| Total Operating Expenses | $38.18M | $34.39M | $30.12M | $25.65M | $22.23M | $24.33M |
| D&A | $1.17M | $817.7K | $765.2K | $670.7K | $1.41M | $1.34M |
| Operating Income | $26.15M | $21.96M | $20.04M | $15.63M | $9.82M | ($756.1K) |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | $5.88M | $5.04M | $4.55M | $3.35M | $510.8K | ($1.99M) |
| Net Income | $22.48M | $19.23M | $17.19M | $12.83M | $9.33M | $1.37M |
| EPS - Basic | $1.77 | $1.52 | $1.36 | $1.02 | $0.76 | $0.11 |
| EPS - Diluted | $1.75 | $1.50 | $1.35 | $1.02 | $0.74 | $0.11 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $51.16M | $52.23M | $49.76M | $57.96M | $62.00M | $50.07M |
| Accounts Receivable | $13.67M | $10.56M | $12.22M | $13.27M | $5.14M | $4.57M |
| Inventory | $11.62M | $10.40M | $12.82M | $5.37M | $4.30M | $3.93M |
| Accounts Payable | $1.82M | $1.90M | $1.86M | $1.80M | $782.9K | $657.1K |
| Current Assets | $81.20M | $75.24M | $76.00M | $77.49M | $76.24M | $63.74M |
| Total Assets | $108.78M | $98.33M | $92.16M | $85.51M | $82.88M | $71.07M |
| Current Liabilities | $10.18M | $8.51M | $16.33M | $8.55M | $6.82M | $4.92M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $14.16M | $11.51M | $20.74M | $11.84M | $10.71M | $9.68M |
| Stockholders' Equity | $94.62M | $86.82M | $71.42M | $73.67M | $72.17M | $61.38M |
| Retained Earnings | $64.23M | $56.79M | $43.26M | $47.26M | $46.99M | $37.67M |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $24.95M | $25.62M | $13.47M | $10.04M | $11.26M | $5.82M |
| Investing Cash Flow | ($8.42M) | ($8.82M) | ($8.01M) | ($1.37M) | $648.2K | $247.0K |
| Financing Cash Flow | ($17.60M) | ($14.34M) | ($13.66M) | ($12.71M) | $24.4K | $522.5K |
| CapEx | $7.76M | $8.01M | $7.44M | $823.0K | $482.3K | $443.0K |
| Free Cash Flow | $17.18M | $17.62M | $6.02M | $9.22M | $10.78M | $5.37M |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 76.7% | 76.9% | 76.5% | 77.4% | 76.6% | 74.3% |
| Operating margin | 31.2% | 30.0% | 30.6% | 29.3% | 23.5% | -2.4% |
| EBITDA margin | 32.6% | 31.1% | 31.7% | 30.6% | 26.8% | 1.8% |
| Net margin | 26.8% | 26.3% | 26.2% | 24.1% | 22.3% | 4.3% |
| Free cash flow margin | 20.5% | 24.1% | 9.2% | 17.3% | 25.8% | 16.9% |
| FCF / Net income | 0.76 | 0.92 | 0.35 | 0.72 | 1.16 | 3.93 |
| R&D / Revenue | 3.5% | 3.9% | 4.4% | 4.3% | 4.6% | 6.0% |
| SG&A / Revenue | 21.2% | 21.8% | 23.1% | 20.1% | 23.4% | 38.7% |
| Effective tax rate | 20.7% | 20.8% | 20.9% | 20.7% | 5.2% | - |
| Return on assets | 20.7% | 19.6% | 18.7% | 15.0% | 11.3% | 1.9% |
| Return on equity | 23.8% | 22.2% | 24.1% | 17.4% | 12.9% | 2.2% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 7.98 | 8.84 | 4.65 | 9.06 | 11.18 | 12.96 |
| Quick ratio | 6.84 | 7.62 | 3.87 | 8.43 | 10.54 | 12.16 |
| Cash ratio | 5.03 | 6.14 | 3.05 | 6.78 | 9.09 | 10.18 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 1.15 | 1.13 | 1.29 | 1.16 | 1.15 | 1.16 |
| Liabilities / Assets | 0.13 | 0.12 | 0.23 | 0.14 | 0.13 | 0.14 |
| Efficiency | ||||||
| Asset turnover | 0.77 | 0.74 | 0.71 | 0.62 | 0.50 | 0.45 |
| Inventory turnover | 1.68 | 1.62 | 1.20 | 2.24 | 2.27 | 2.07 |
| Days sales outstanding | 60d | 53d | 68d | 91d | 45d | 53d |
| Days inventory outstanding | 218d | 225d | 304d | 163d | 161d | 176d |
| Days payable outstanding | 34d | 41d | 44d | 55d | 29d | 29d |
| Cash conversion cycle | 243d | 236d | 328d | 199d | 176d | 200d |
| Valuation | ||||||
| P / E | 55.6x | 36.7x | 35.2x | 27.7x | 62.4x | 207.3x |
| P / B | 13.2x | 8.1x | 8.5x | 4.9x | 8.1x | 4.6x |
| P / S | 14.9x | 9.6x | 9.2x | 6.7x | 13.9x | 8.9x |
| EV / EBITDA | 43.9x | 28.6x | 26.6x | 18.4x | 46.3x | 400.8x |
| Growth | ||||||
| Revenue growth (YoY) | 14.4% | 11.7% | 23.0% | 27.5% | 31.8% | -17.7% |
| Revenue CAGR (3y) | 16.3% | 20.5% | 27.4% | 11.4% | 8.8% | 11.2% |
| Revenue CAGR (5y) | 21.5% | 13.7% | 15.1% | 18.2% | 5.2% | 0.1% |
| Gross profit growth (YoY) | 14.2% | 12.3% | 21.5% | 28.8% | 36.0% | -20.6% |
| Operating income growth (YoY) | 19.0% | 9.6% | 28.2% | 59.2% | - | - |
| Net income growth (YoY) | 16.9% | 11.9% | 34.0% | 37.6% | 581.2% | -85.8% |
| EPS growth (YoY) | 16.7% | 11.1% | 32.4% | 37.8% | 572.7% | -85.9% |
| EPS CAGR (3y) | 19.7% | 26.6% | 130.7% | 9.4% | 12.5% | 40.1% |
| EPS CAGR (5y) | 73.9% | 14.0% | 21.0% | 91.1% | 4.3% | -28.8% |
| FCF growth (YoY) | -2.5% | 192.5% | -34.7% | -14.4% | 100.5% | -45.5% |
| FCF CAGR (5y) | 26.2% | 12.3% | -3.4% | 1.3% | 4.6% | -6.1% |
| Book value growth (YoY) | 9.0% | 21.6% | -3.1% | 2.1% | 17.6% | 10.6% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Geographic
$83.81M totalUS$70.56M · 84.2%
Non Us$13.26M · 15.8%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
5.29
Safe
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
6/9
Neutral
- ✓Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- ✗Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing IRADIMED CORP against the 5 most active filers in the same SIC group.
Dividends
$1.24/share trailing 12 months · +93.8% YoY
| Ex-date | Per share |
|---|---|
| May 15, 2026 | $0.2000 |
| Feb 23, 2026 | $0.2000 |
| Dec 17, 2025 | $0.5000 |
| Nov 14, 2025 | $0.1700 |
| Aug 18, 2025 | $0.1700 |
| May 20, 2025 | $0.1700 |
| Feb 24, 2025 | $0.1700 |
| Nov 15, 2024 | $0.1500 |
| Aug 20, 2024 | $0.1500 |
| May 17, 2024 | $0.1500 |
| Dec 21, 2023 | $0.6300 |
| Feb 10, 2023 | $1.0500 |
| Feb 16, 2022 | $1.0000 |